Literature DB >> 7112507

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.

E Holmer, C Mattsson, S Nilsson.   

Abstract

Heparin and heparin fragments of different molecular weight and with different anti-factor Xa/APTT activity ratios were studied with respect to their ability to inhibit thrombus formation in an animal model. It is concluded that: a) Neither anti-factor Xa nor the APTT activity alone is a good reflector of the antithrombotic activity. b) Anti-factor Xa active fragments must have a minimum molecular weight in order to elicit good antithrombotic activity. c) High affinity for antithrombin III is important for good antithrombotic activity. d) A heparin fragment of molecular weight 4 000 has the same antithrombotic activity as heparin but less effect on the clotting time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7112507     DOI: 10.1016/0049-3848(82)90089-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

2.  A low molecular weight heparin in hemodialysis.

Authors:  N Maurin; H Kierdorf
Journal:  Klin Wochenschr       Date:  1988-03-15

Review 3.  Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

Authors:  Jeremy W Vandiver; Leticia I Ritz; Jeffrey T Lalama
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

4.  Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 5.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

6.  [Use of low molecular-weight heparin in hemodialysis patients].

Authors:  J Schrader; J Rieger; H Müschen; W Stibbe; H Köstering; P Kramer; F Scheler
Journal:  Klin Wochenschr       Date:  1985-01-15

7.  Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III.

Authors:  C Mattsson; M Hoylaerts; E Holmer; T Uthne; D Collen
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

Review 9.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 10.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.